Mitsubishi Chemical Group (4188) investor relations material

Executive summary

• FY 2025 saw core operating income down 2% to ¥225.0 billion, operating income plunging 79% to ¥30.1 billion, and profit attributable to owners down 74% to ¥11.8 billion, mainly due to non-recurring items and restructuring costs.

• Major structural reforms included withdrawal from coke and carbon materials, ethylene restructuring, dissolution of overseas MMA JVs, and voluntary retirement programs.

• Specialty Materials performed steadily, but MMA and Basic Materials & Polymers faced a sluggish environment and asset impairments.

• Management acknowledged exceptional circumstances and implemented executive pay cuts as accountability.

• The transfer of Mitsubishi Tanabe Pharma Corporation (MTPC) was completed, with MTPC and its affiliates now classified as discontinued operations.

Financial highlights

• FY 2025 sales revenue was ¥3,704.0 billion, down 6% year-on-year, with core operating income at ¥225.0 billion, down 2%.

• Operating income fell 79% to ¥30.1 billion; net income from discontinued operations was ¥94.8 billion, mainly from the MTPC transfer.

• Free cash flow increased to ¥560.8 billion, up from ¥277.4 billion in the prior year, driven by asset sales.

• Net interest-bearing debt decreased to ¥387.5 billion, with the net D/E ratio improving to 0.83.

• Cash and cash equivalents at year-end rose to ¥527.1 billion, up ¥201.0 billion.

Outlook and guidance

• FY 2026 core operating income is forecast at ¥305.0 billion, up 36% year-on-year, with net income attributable to owners expected to rise to ¥127.0 billion.

• FY 2027 guidance projects sales revenue of ¥3,800.0 billion and net income of ¥227.0 billion.

• Dividend forecast for FY 2026 is ¥32 per share, unchanged from FY 2025.

• Forecasts exclude potential impacts from Middle East tensions, which could reduce core operating income by ¥18.0 billion if disruptions persist.